What is Lightcast?
Lightcast is a pioneering biotechnology firm specializing in next-generation microfluidic platforms that redefine the boundaries of complex cell analysis. By enabling the independent and parallel manipulation of thousands of individual cells, the company provides researchers with unprecedented control over cell culture and assay processes. This technological capability is instrumental in shortening the complexity of cell analysis workflows, thereby accelerating the discovery of new clinical approaches and innovative therapies. Positioned at the intersection of deeptech and life sciences, Lightcast serves as a vital partner to academic institutes and biopharmaceutical organizations seeking to push the frontiers of modern medicine.
How much funding has Lightcast raised?
Lightcast has raised a total of $77.5M across 3 funding rounds:
Seed
$1.5M
Series B
$49M
Unspecified
$27M
Seed (2019): $1.5M, investors not publicly disclosed
Series B (2023): $49M led by Merck Ventures, Illumina Ventures, ARCH Venture Partners, and Omx Ventures
Unspecified (2026): $27M supported by Merck Ventures, Omx Ventures, Longwall Ventures, Illumina Ventures, and ARCH Venture Partners
Key Investors in Lightcast
Merck Ventures
M Ventures is the strategic, corporate venture capital arm of Merck, investing globally in transformational ideas and early-stage technologies that impact core business areas.
Illumina Ventures
Illumina Ventures is a leader in genomics and precision health investing, focused on building an ecosystem that translates investment into innovation to enhance human health.
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often cofounding startups with scientists.
What's next for Lightcast?
With the support of this major strategic investment, Lightcast is poised to transition from its current pilot-focused phase toward broader commercial integration. The company is expected to leverage this capital to scale its manufacturing capabilities and expand its footprint within the global pharmaceutical R&D ecosystem. Future strategic initiatives will likely focus on deepening collaborations with industry incumbents to integrate its microfluidic solutions into standard drug discovery pipelines. As the company matures, the focus will shift toward long-term sustainability and the commercialization of its platform as a foundational tool for the next generation of precision medicine and synthetic biology applications.
See full Lightcast company page
